While nonprostatic PSMA uptake hampers accuracy in prostate cancer staging, it also expands potential applications of PSMA PET, which as a result has been proposed for staging and restaging of other malignancies such as RCC [32, 33]. This evidence concerns the gene FOLH1 and renal cell carcinoma.